JP Morgan Day 3: Intercept makes an appearance; Sarepta waits for FDA notes
This article was originally published in Scrip
Executive Summary
Diversified big pharma and specialty pharmaceutical players have multiple pipeline programs to discuss with investors during the 32nd Annual JP Morgan Healthcare Conference, but news about a single drug candidate has the potential to make or break smaller companies.